Search Results 481-490 of 17848 for Coagulation

1. Atezolizumab Immunotherapy in Patients With Advanced NSCLC (AJCC 7th Edition) - Mayo Clinic

   Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects. Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC ...

2. Vedolizumab IV in Pediatric Participants With Ulcerative Colitis or Crohn's Disease - Mayo Clinic

   ... coagulation, immunological, endocrine/metabolic, neurological, or other medical disorder that, in the opinion of the investigator, would confound the study ...

3. A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With MM - Mayo Clinic

   Coagulation test: INR or PT: ≤ 1.5 x ULN unless subject is receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended ...

4. Coarctation Of The Aorta Clinical Trials - Mayo Clinic Research

   This study is designed to determine if exercise echocardiography will identify ventricular and vascular function abnormalities in patients with COA that are not ...

5. Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202) - Mayo Clinic

   Coagulation: INR or PT: ≤1.5xULN unless subject is receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended use of ...

6. A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment - Mayo Clinic

   Adequate coagulation studies (obtained ≤ 14 days prior to randomisation) as demonstrated by prothrombin time and partial thromboplastin time within normal ...

7. A Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy in Patients with Gastric or Gastroesophageal Cancer - Mayo Clinic

   archived specimen). 10. ECOG performance status ≤ 1 within 7 days of first dose of study drug 11. Acceptable liver, renal, hematologic, and coagulation ...

8. Open-Label extension study of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis - Mayo Clinic

   History of intracranial hemorrhage, arteriovenous malformation, bleeding disorder, and coagulation disorders. An uncontrolled thyroid disorder. Uncontrolled ...

9. Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery - Mayo Clinic

   NOTE: Heparin for line patency without detectable lab abnormalities for coagulation will be allowed. Corticosteroid use ≤ 14 days prior to registration ...

10. First-in-Human Study of FLX925 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia - Mayo Clinic

    Normal coagulation profile as evidenced by PT and aPTT ≤ 1.5 x ULN; For women of childbearing potential, negative serum pregnancy test; Women of childbearing ...